+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free

Anti-Infective Antibodies Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

Pre Book Price: $ 5216

Original Price: $ 5795

Anti-infective antibodies are being used extensively nowadays to treat serious bacterial and viral diseases such as pneumonia, tuberculosis and malaria. According to the World Health Organization, six major infectious diseases namely diarrhea, pneumonia, malaria, acquired immune deficiency syndrome (AIDS) , measles and tuberculosis are responsible for half of the premature deaths worldwide killing children and young adults. Moreover, threatening pandemics such as H1N1 influenza A virus (swine flu) is also adding pressure on healthcare sector. On the basis of these diseases which are being treated with the help of anti-infective antibodies, this market is divided into four major segments namely recombinant antibodies for viral diseases, recombinant antibodies for bacterial diseases, human plasma-derived immunoglobulins and Varicella Zoster immunoglobulins (VZIG). On the basis of disease causing microbe, recombinant antibodies for viral diseases are further characterized into:
  • Respiratory syncytial virus (RSV)
  • Hepatitis C virus (HCV)
  • Herpes simplex virus
  • Influenza virus
  • Cytomegalovirus (CMV)
  • Hemorrhagic fever viruses
  • Rabies virus
  • Human immune deficiency virus (HIV)
Similarly, recombinant antibodies for bacterial diseases are divided into following segments on the basis of disease causing micro-organisms:
  • Bacillus Anthracis
  • Pseudomonas
  • Staphylococci
  • Clostridium Difficile
  • Streptococci
  • Clostridium Botulinum
Human plasma-derived immunoglobulins include the antibodies which are derived by human blood plasma differentiation. On the basis of the different administration method, the market is divided into five major categories which include:
  • Conventional intravenous immunoglobulins (IVIG)
  • Injectable SC/IM immunoglobulins
  • Enriched immunoglobulins
  • Oral immunoglobulins
  • Hyperimmunes
Varicella Zoster Immunoglobulins (VZIG) includes all the anti-infective antibodies which work against the diseases caused by varicella zoster virus. This segment of the anti-infective antibodies market is fragmented on the basis of the immunoglobulins used to treat specific disease conditions which consist of following categories:
  • Tetanus immunoglobulins
  • Cytomegalovirus immunoglobulins
  • Rabies immunoglobulins
  • Hepatitis A immunoglobulins
  • Hepatitis B immunoglobulins
  • Vaccinia immunoglobulins
Among the mentioned anti-infective antibodies, the major market share is captured by recombinant antibodies for viral diseases followed by recombinant antibodies for bacterial diseases due to high prevalence of these diseases worldwide. According to the World Health Organization reports, 13.3 million people were suffering from AIDS in 2013 all over the world. Among the different antibodies available, the major anti-infective antibodies which are revolutionizing the market include truvada and valtrex, which are anti-HIV and anti-herpes antibodies respectively.

Additionally, the growing emergence of antibody resistant microorganisms, lethal virus and threat from engineered microorganisms is stimulating the interest of researchers towards developing novel anti-infective antibodies. Advances in understanding the mechanisms and new anti-bodies technologies are also contributing for the growing class of anti-infective antibodies in research and development. In anti-infective antibodies market, large numbers of companies are undergoing clinical trials as for instance, Novaratis AG is performing Phase IIb clinical trials of Albuferon, drug for the treatment of hepatitis C and Roche Pharma AG has announced positive results for PEGASYS combination therapy, treatment for hepatitis C. 

Companies based in North America and Europe is extensively performing research and development in anti-infective antibodies segment. The major key players which are involved in production and research and development in anti-infective drugs market include Novaratis AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Gilead Sciences, Pfizer, Inc., Abbott Laboratories, Sanofi S.A., Johnson & Johnson and Bristol-Myers Squibb.

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. Geographies analyzed under this research report include 
  • North America 
  • Asia Pacific 
  • Europe
  • Rest of the World  
This report provides comprehensive analysis of 
  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for upcoming years 
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis. 

Reasons for Buying this Report
  • This report provides pin-point analysis for changing competitive dynamics
  • It provides a forward looking perspective on different factors driving or restraining market growth 
  • It provides a six-year forecast assessed on the basis of how the market is predicted to grow 
  • It helps in understanding the key product segments and their future
  • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
  • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments 
  • It provides distinctive graphics and exemplified SWOT analysis of major market segments

To receive discount, please click on the button below.

Please click on the button below to customize this report.

Back To Top